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Abstract  
Bone mineralization is a carefully orchestrated process, regulated by a number of promoters 
and inhibitors that function to ensure effective hydroxyapatite formation. Here we sought to 
identify new regulators of this process through a time series microarray analysis of 
mineralising primary osteoblast cultures over a 27 day culture period.  To our knowledge this 
the first microarray study investigating murine calvarial osteoblasts cultured under conditions 
that permit both physiological extracellular matrix mineralization through the formation of 
discrete nodules and the terminal differentiation of osteoblasts into osteocytes. RT-qPCR was 
used to validate and expand the microarray findings. We demonstrate the significant up-
regulation of >13,000 genes during the osteoblast mineralization process, the highest-ranked 
differentially expressed genes of which were dominated by members of the PPAR-γ 
signalling pathway, namely Adipoq, Cd36 and Fabp4. We also identify Cilp, Phex, Trb3, 
Sox11, Psat1 and Ptgs2 as novel regulators of matrix mineralization. Further studies 
examining the precise function of the identified genes and their interactions will advance our 
understanding of the mechanisms underpinning biomineralization.   
 
 
  Introduction 
During endochondral bone formation, chondrocytes and osteoblasts mineralize their 
extracellular matrix (ECM) by promoting the initial formation of crystalline hydroxyapatite 
(HA) in the sheltered interior of membrane-limited matrix vesicles (MVs) [2]. This is 
followed by the modulation of matrix composition to further promote propagation of HA 
outside of the MVs [Anderson et al., 1990].  This biphasic mineralization process is critically 
dependent  on a regulated balance of a number of factors which include calcium and 
inorganic phosphate (Pi), ECM proteins, and the presence of mineralization inhibitors such as 
inorganic pyrophosphate (PPi), matrix gla protein, and osteopontin [Meyer, 1984; Sodek et al, 
2000; Murshed et al, 2004; Johnson et al, 2000].  Three osteoblast molecules have been 
identified as affecting the controlled deposition of HA by regulating the extracellular levels 
of PPi, and in turn, of osteopontin: tissue-nonspecific alkaline phosphatase (TNAP), ecto-
nucleotide pyrophosphatase/phosphodiesterases-1 (NPP1) and the ankylosis protein (ANK) 
(Johnson et al, 2000; Johnson et al, 2003; Hessle et al, 2002; Harmey et al, 2004; Harmey et 
al, 2006).  
TNAP is responsible for the generation of Pi from its substrate PPi for HA crystallisation 
(Fallon et al., 1980) and the restriction of PPi, to maintain a Pi/PPi ratio permissive for normal 
bone mineralization (Harmey et al, 2004; Addison et al., 2007). NPP1 inhibits HA 
precipitation by its PPi-generating properties within the ECM whereas ANK functions as a 
transmembrane PPi-channeling protein, allowing PPi molecules to pass through the plasma 
membrane from the cytoplasm to ECM ((Johnson et al., 1999; Numberg et al., 2001).  The 
bone specific phosphatase PHOSPHO1 is also essential for the accumulation of Pi within 
MVs and bone mineralization.[13-18] Indeed, we have found that PHOSPHO1 and TNAP 
have non-redundant functions in regulating HA formation and mineralization; genetic 
ablation of either produces a hypomineralised, functionally-impaired skeleton and 
spontaneous fracture, and simultaneous ablation, a complete lack of all skeletal 
mineralisation (yadav et al; huesa et al) 
Further mechanisms unrelated to the supply and hydrolysis of PPi also exist to control matrix 
mineralization. Extracellular nucleotides adenosine triphosphate (ATP), and uridine 
triphosphate (UTP) signal via the P2Y2 receptor to inhibit bone mineralization (Orriss et al, 
2007), and that the ATP-sensitive P2X1 and P2X7 receptors also negatively regulate bone 
mineralization (Orriss et al, 2012). Recent progress has also identified roles for key non 
collagenous proteins in the regulation of HA crystal initiation and propagation, including 
bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), dentin matrix protein 1 (DMP1) 
and matrix extracellular phosphoglycoprotein (MEPE).[30] Furthermore, the formation of 
multicellular networks permeating the mineralized ECM by osteocytes may play pivotal 
mechano-modulatory roles in directing bone formation and mineralization (Burger and Klein-
Nulend, 1999). 
Despite these recent advances in our knowledge, the full mechanisms underpinning osteoblast 
matrix mineralization have yet to be fully elucidated. In the present study we have exploited a 
microarray approach to identify novel genes that are differentially expressed during the 
mineralization process. To our knowledge this the first microarray study investigating murine 
calvarial osteoblasts cultured under conditions that permit both physiological ECM 
mineralization through the formation of discrete nodules and terminal differentiation of 
osteoblasts into osteocytes. The identification of novel differentially expressed genes during 
the process of bone mineralization may open up new potential avenues for the therapeutic 
  treatment of clinical mineralization disorders including osteoporosis, osteopetrosis and 
vascular calcification.  
Materials and methods 
Ethics statement 
All animal experiments were approved by The Roslin Institute's Animal Users Committee 
and the animals were maintained in accordance with Home Office (UK) guidelines for the 
care and use of laboratory animals. 
Primary osteoblast isolation 
Primary mouse calvarial osteoblasts were obtained from 3-day old C57Bl/6 mice by 
sequential enzyme digestion of excised calvarial bones using a four-step process [1 mg/ml 
collagenase type II in Hanks' balanced salt solution (HBSS) for 10 min; 1 mg/ml collagenase 
type II in HBSS for 30 min; 4 mM ethylenediaminetetraacetic acid (EDTA) for 10 min; 1 
mg/ml collagenase type II in HBSS for 30 min]. The first digest was discarded and the cells 
subsequently obtained were resuspended in growth medium consisting of α-MEM 
(Invitrogen, Paisley, UK) supplemented with 10% FCS (Invitrogen) and 1% gentamycin 
(Invitrogen). Cells were cultured for 4 days in a humidified atmosphere (95% air/5% CO2, 
37°C) in T75 tissue culture flasks (Greiner Bio-One, GmbH, Frickenhausen, Baden-
Württemberg, Germany) until confluent. 
Primary osteoblast culture 
Osteoblasts were seeded at a density of 1.5×104 cells/cm2 in ???????. At confluency (day 0), 
growth medium was supplemented with 2.5mM ßGP and 50 µg/ml ascorbic acid for up to 28 
days to induce matrix calcification. Incubation was at 37°C in a humidified atmosphere of 
95% air/5% CO2 and the medium was changed every second/third day. Previous studies have 
shown that during this 28 day culture period, murine calvarial osteoblastcultures display 
increasing ECM mineralization associated with elevated TNAP activity and the up-regulation 
of osteocyte markers, DMP1, E11 and sclerostin.[31, 32] This in vitro model mimics the full 
osteoblast differentiation cascade observed in vivo and is therefore appropriate for the 
identification of potential novel regulators of matrix mineralization.  
cDNA microarray hybridisation 
For microarray analysis, RNA was extracted from cells at days 0, 9 and 27 of culture using 
RNeasy mini kit (Qiagen Ltd, Crawley, West Sussex, UK), according to the manufacturer's 
instructions. For each sample, total RNA content was assessed by absorbance at 260 nm and 
purity by A260/A280 ratios. The quality of each sample was considered suitable by a ratio of 
greater than 1.9. Samples were sent to Ark Genomics (The Roslin Institute, University of 
Edinburgh, UK) where target preparation and hybridisation to the Affymetrix Murine 430 2.0 
GeneChip was carried out following the standard Ark Genomics protocols  (http://www.ark-
genomics.org/protocols). This GeneChip contains ∼39,000 full-length mouse genes and EST 
clusters from the UniGene database. The data obtained from these hybridisations can be 
viewed on the EMBL-EBI Array Express repository (http://www.ebi.ac.uk/microarray-
as/aer/?#ae-main[0]) (accession no. E-MEXP-1244).  
 
 
  Microarray data analysis 
Normalisation across all arrays was achieved using the robust multi-array average (RMA) 
expression measure which results in expression measures (summarised intensities) in log base 
2.[34] Comparisons were undertaken using linear modelling. Subsequently, empirical 
Bayesian analysis was applied (including vertical (within a given comparison) p value 
adjustment for multiple testing, which controls for false discovery rate) for which the 
Bioconductor package limma was used [33]. An overview of the underlying biological 
changes occurring within each comparison can be obtained by functional enrichment 
analysis. This was performed from two perspectives, namely KEGG pathway membership 
and Gene Ontology (GO) terms. The level of statistical significance for functional analysis 
was chosen to be the most stringent level at which 1% of the array features were, on average, 
significant. For the current dataset, adjusted p<0.0001 was appropriate for the comparisons 
performed. Significant genes (adjusted p<0.0001) from each comparison were analysed for 
enrichment of KEGG pathways and GO terms using separate hypergeometric tests. 
Enrichment (p<0.001) was assessed for up-regulated and down-regulated pathways and genes 
separately. 
Detection of mineralization 
Calcium deposition was evaluated by alizarin red staining (Zhu et al, 2011 Staines et al, 
2012). Cells were washed with phosphate buffered saline (PBS), fixed in 4% 
paraformaldehyde for 5 min at 4ºC, stained with 2% alizarin red (pH 4.2) for 10 min at room 
temperature and rinsed with distilled water. 
Analysis of gene expression using quantitative RT-PCR 
Quantitative PCR (qRT-PCR) was used to confirm changes in the expression of selected 
genes. RNA was extracted at days 0, 7, 14, 21 and 28 of culture using RNeasy mini kit 
(Qiagen) according to the manufacturer’s instructions. For each sample, total RNA content 
was assessed by absorbance at 260nm and purity by A260/A280 ratios. RNA was reverse 
transcribed and the PCR reaction undertaken as described previously.[35, zhu et al 2011; 
macrae et al 2009] All genes were analysed with the SYBR green detection method using the 
Stratagene Mx3000P real-time qPCR system (Stratagene, CA, USA). Each PCR was run in 
triplicate. All gene expression data were normalised against Gapdh and the control values 
expressed as 1 to indicate a precise fold change value for each gene of interest. All primers 
were purchased from Qiagen (sequences unknown), with the exception of Gapdh (sequence 
unknown) and Phex (forward: CTAACCACCCACTCCCACTT, reverse: 
CCAATAGACTCCAAACCTGAAGA) which were purchased from Primer Design 
(Southampton, UK).  
Results 
Total RNA isolated from primary osteoblasts at 0, 9 and 27 days of culture was hybridised to 
Affymetrix Murine 430 2.0 Array. Analysis in Bioconductor limma software demonstrated 
that following normalisation, 13,812 genes were up-regulated and 17,403 genes down-
regulated following 9 days of culture (n=4, >1.5 fold change). 14,834 genes were up-
regulated and 14,072 down-regulated at day 27 of culture, in comparison to day 0 (n=4, >1.5 
fold change). The top twenty up-regulated and down-regulated genes at day 9 and day 27 are 
listed in Table 1 and Table 2 respectively.  
  Transcripts significantly up-regulated during mineralization at both day 9 and day 27 
compared to day 0 included key members of the peroxisome proliferator-activated receptor 
gamma (PPAR-γ) signaling pathway, namely adiponectin (Adipoq), cluster of differentiation 
36 (Cd36), and fatty acid binding protein 4 (Fabp4). Cartilage intermediate layer protein 
(Cilp) and phosphate-regulating neutral endopeptidase (Phex) were also markedly up-
regulated (Table 1). Conversely, transcripts significantly down-regulated included Tribbles 3 
(Trib3), phosphoserine aminotransferase 1 (Psat1) and sex determining region Y-box (Sox11) 
(Table 2). Functional enrichment analysis identified the significant up-regulation of the 
PPAR-γ signalling pathway (Figure 1). 
To confirm and extend these data, further gene expression studies were undertaken in 
calvarial osteoblasts cultured for 28 days under mineralising conditions, and sampled at 
regular intervals. Calvarial osteoblasts at confluency had negligible amounts of alizarin red 
staining (calcium deposition) (Fig. 2a).  Further culture in mineralising conditions for an 
additional 7, 14, 21 and 28 d resulted in the formation of discrete nodules, as detected by 
increased alizarin red staining.   In addition, significant increases in mRNA expression of key 
genes associated with osteoblast mineralization, tissue non-specific alkaline phosphatase 
(Alpl) (X fold change; P<0.001) and osteocalcin (X fold change; P<0.001), were observed at 
day 7, with increased expression maintained throughout the culture period (Fig. 2b and c 
respectively). These data confirm the formation of calcified matrix in calvarial osteoblasts 
over the 28-day time course examined.  
To validate the microarray expression data, the eight mineralization-responsive genes listed 
above were selected for analysis of gene expression by qRT-PCR. Analysis at day 7 revealed 
significant increases in the mRNA expression of Adipoq (x fold change; P<0.001), Cd36 (x 
fold change; P<0.001), Fabp4 (x fold change; P<0.001), Cilp (X fold change; P<0.001) and 
Phex (x fold change; P<0.001). Increased expression of these genes was maintained 
throughout the culture period (Fig. 3). The induction of these genes therefore paralleled the 
expression patterns obtained by microarray analysis. Similarly, a significant down-regulation 
of Trib3 (x fold change; P<0.001), PsatI (x fold change; P<0.001) and Sox1 1(x fold change; 
P<0.001) was detected by qRT-PCR analysis at day 7. Reduced expression of these genes 
was also observed throughout the culture period (Fig. 4). Together our data have identified 
eight genes differentially expressed during the process of calvarial osteoblast mineralization 
under conditions that permit both physiological ECM mineralization and terminal 
differentiation into osteocytes. 
Discussion 
Whilst numerous in vivo and in vitro studies have examined the mechanisms of osteoblast 
differentiation and mineralization, few have incorporated the transition from osteoblasts to 
osteocytes. Osteocytes are non-proliferative, terminally differentiated cells in the osteoblast 
lineage, and the most abundant cell type in bone. Recent studies have indicated that 
osteocytes function as a mechanosensor in the bone, coordinate bone homeostasis, and 
secrete phosphate regulating molecules (Bonewald, 2011). To our knowledge this is the first 
microarray study to investigate murine calvarial osteoblasts that terminally differentiate into 
osteocytes. 
 
βGP is an exogenous phosphate source which acts as a substrate for ALP. Therefore cells 
treated with βGP dictate when the Pi is released through their differentiation and expression 
of ALP. Previous studies have demonstrated that widespread dystrophic deposition of mineral 
occurs in calvarial osteoblasts cultured with high concentrations (10mM) of βGP (Orriss et al, 
  2007). Therefore in the present study, murine calvarial osteoblasts were cultured with 2.5mM 
βGP, and reproducibly formed abundant, discrete nodules with characteristic trabecular 
morphology; alizarin red staining revealed that mineralization was exclusively confined to 
defined regions of these matrix structures. This is the first study to undertake a microarray 
analysis of mineralising murine calvarial osteoblasts treated with physiological levels of βGP.  
 
Despite recent advances in our knowledge, the full mechanisms underpinning osteoblast 
matrix mineralization have yet to be fully elucidated. This study has clearly demonstrated 
differential expression of novel genes in mineralising primary calvarial osteoblast cultures. 
Furthermore, many of these genes have not been reported in previous osteoblast 
mineralization microarray studies (Doi et al., 2001). These marked differences are likely to be 
directly attributable to the culture conditions in the present study that enabled the 
physiological mineralization of the ECM and the terminal differentiation of osteoblasts into 
osteocytes in vitro. 
 
Microarray analysis, functional enrichment and qRT-PCR validation studies together 
identified the up-regulation of Adipoq, Cd36 and Fabp4 during in vitro osteoblast 
mineralization, key genes involved in the Peroxisome Proliferator-Activated Receptor 
Gamma (PPAR-γ) signalling pathway and adipogenesis. Cd36, also known as fatty acid 
translocase (FAT), is a long chain fatty acid transporter which is present at the plasma 
membrane and activates the PPARs [36]. Fabp4 and Adipoq act downstream of PPAR-γ, and 
have both previously been shown to be involved in adipocyte differentiation (Fig. 3). Fabp4 
is a member of the FABP family of which nine isoforms have been identified which have 
been localised to mature adipocytes and adipose tissue.[47] Similarly, Adipoq is strongly 
expressed by adipocytes and is known to stimulate the differentiation of osteoblasts through 
the induction of prostaglandin-endoperoxide synthase 2 and bone morphogenetic protein 2 
(BMP2) in mesenchymal cells.[48]  
Previous microarray analysis of mesenchymal lineage markers in mouse calvaria cell cultures 
have indicated that adipocyte-asssociated genes are transcriptionally induced together with 
osteoblast-associate genes during osteoblast development (Garcia et al., 2002). Similarly, 
data has shown that adipocytes emerge along with osteogenic potential in a fraction of fetal 
rat calvaria cells treated with BRL-49653, a synthetic ligand for PPARγ (Hasegawa et al., 
2008). The demonstration that a subset of osteoblasts maintain capacity for adipogenic fate 
selection, even at relatively mature developmental stages implies an unexpected plasticity 
with important implications in normal and pathological bone development (Yoshiko et al., 
2010). The molecular basis by which this subset of osteogenic cells acquires high endogenous 
expression of adipogenic transcription factors, and the functional significance of this 
acquisition, remains to be determined. 
This study has also identified the up-regulation of Phex during in vitro osteoblast 
mineralization. Phex gene homology with members of the M13 membrane-bound zinc 
metalloendopeptidase family. It has been proposed that a mutation in the human PHEX gene 
is directly responsible for the phenotypic changes in patients with X-linked 
hypophosphatemia (Holm et al., 1997). Investigation of murine tissues and cell cultures has 
revealed that Phex is predominantly expressed in bones and teeth (Du et al, 1996; Ruchon et 
al., 1998). Within bone, Phex expression is limited to cells of the osteoblast lineage - 
osteoblasts, and osteocytes (Ruchon et al, 1998; Thompson et al., 2002).  
  PHEX has not been reported to have any direct effects on mineralization, however it is able 
to rescue the inhibitory effects of the MEPE-ASARM peptide by preventing its release and 
by proteolytically cleaving the ASARM peptide deeming it inactive.[35, 50, 51] Furthermore, 
it is well established that the increased expression of ASARM peptides are responsible for the 
mineralization defect observed in the Hyp mouse model, a model for XLH caused by an 
inactivating mutation in Phex.[52] The increased expression of Phex observed here is 
therefore indicative of the emerging evidence for a critical role of the ASARM peptides in 
matrix mineralization.  
 
Our data also demonstrate an increased expression of Cilp during osteoblast mineralization. 
CILP is a key ECM component, expressed predominantly in the articular cartilage.[53] 
Studies in chondrocytes have demonstrated that both transforming growth factor beta (TGFβ) 
and insulin-like growth factor 1 (IGF1) induce Cilp expression [56]. Whilst Cilp has been 
implicated in numerous diseases of cartilage, to our knowledge this the first report of CILP 
expression within osteoblasts. This data, together with previous studies showing that CILP 
may generate extracellular PPi,[56], highlight the requirement for further investigations into 
the role of CILP in controlling bone mineralization, potentially through modulation of Pi/PPi 
balance.  
 
The results presented here have also identified the down-regulation of Sox11 during 
osteoblast differentiation and matrix mineralization. Sox11 is a transcription factor which is 
expressed during embryonic development and tissue remodelling.[57] Whilst this is the first 
report of altered Sox11 expression in osteoblasts, previous microarray studies have shown 
that Sox11 is differentially expressed during the initiation of chondrogenesis (Cameron et al, 
2009). Additionally, Sox11 null mice display craniofacial and skeletal malformations, and 
delayed endochondral ossification.[58] Further studies are therefore required to elucidate the 
mechanisms through which Sox11 modulates chondrocyte and osteoblast dynamics. 
 
The Psat1 gene codes for a phosphoserine aminotransferase which is involved in cell 
proliferation in vitro [59]. To our knowledge, this is the first demonstration of reduced 
expression of Psat1 during osteoblast ECM mineralization.  However, a recent study 
analysing the genes involved in mineralization during differentiation of human periodontal 
ligament stem cells, also noted a significant down-regulation of Psat1 expression (Choi et al, 
2011). Together these data suggest a key role for Psat1 in regulating biomineralization across 
a range of tissue types. 
 
The present study also provides evidence for the down-regulation of Trib3. In fact this was 
the most highly ranked down-regulated gene following both 9 and 27 days of culture. This 
homolog of the Tribbles family plays a key role in the regulation of nuclear factor of 
activated B cells (NF-kappaB) activation, which is known to inhibit osteoblastic bone 
formation.[60] Furthermore, TRIB3 stabilises the expression of SMAD, the major BMP 
signalling transcription factor, through its dissociation from the BMPII receptor and its 
promotion of the subsequent degradation of Smad ubiquitin regulatory factor 1. Therefore 
through this mechanism, TRIB3 has the ability to promote osteogenic differentiation and 
mineralization.[61] In addition, the BMP signalling pathway has been shown in numerous 
studies to interact with the Wnt signalling pathway to potentiate its effects on osteoblast 
differentiation.[62] Sclerostin, a marker of mature deeply embedded osteocytes exerts 
negative effects of on osteoblastogenesis and bone formation through activation of the Wnt 
signalling pathway and BMP antagonism [63]. It is therefore plausible that the decreased 
  expression of Trib3 observed in the present study reflects the terminal differentiation of the 
osteoblast into the osteocyte.[64]  
 
In conclusion, this study exemplifies that the use of array technologies represents a powerful 
method for the discovery of genes involved in bone mineralization.  These results will enable 
future investigations into the precise mechanisms underpinning osteogenic differentiation. 
Furthermore, our data will inform future investigations into the molecular mechanisms 
surrounding diseases of biomineralization such as osteomalacia, vascular calcification and 
osteoporosis.  
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